These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 578232)
1. Evaluation of amikacin sulfate (Amikin). A new aminoglycoside antibiotic. Schiffman DO JAMA; 1977 Oct; 238(14):1547-50. PubMed ID: 578232 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate. Pien FD; Ho PW Am J Hosp Pharm; 1981 Jul; 38(7):981-9. PubMed ID: 7020413 [TBL] [Abstract][Full Text] [Related]
3. [Experimental study of the antibacterial activity and chemotherapeutic effectiveness of amikacin sulfate]. Lobuseva AN; Kuznetsova SM; Samoĭlova LN Antibiot Med Biotekhnol; 1985 Oct; 30(10):776-80. PubMed ID: 4091515 [TBL] [Abstract][Full Text] [Related]
4. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy. Saavedra S; Vera D; Ramírez-Ronda CH Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877 [TBL] [Abstract][Full Text] [Related]
5. Amikacin therapy of severe infections produced by gram-negative bacilli resistant to gentamicin. Valdivieso M; Bodey GP Am J Med Sci; 1977; 273(2):177-84. PubMed ID: 860733 [TBL] [Abstract][Full Text] [Related]
6. Antibiotic resistance patterns during aminoglycoside restriction. Young EJ; Sewell CM; Koza MA; Clarridge JE Am J Med Sci; 1985 Dec; 290(6):223-7. PubMed ID: 3936358 [TBL] [Abstract][Full Text] [Related]
7. Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms. Yu VL; Rhame FS; Pesanti EL; Axline SG JAMA; 1977 Aug; 238(9):943-7. PubMed ID: 328950 [TBL] [Abstract][Full Text] [Related]
8. An overview of amikacin. Ristuccia AM; Cunha BA Ther Drug Monit; 1985; 7(1):12-25. PubMed ID: 3887667 [TBL] [Abstract][Full Text] [Related]
9. [Clinical and bacteriological evaluation of Amikin (Amikacin sulfate) by Bristol-Myers]. Wencel J; Czaplicki M; Borkowski A; Malewski AW Pol Tyg Lek; 1978 Dec; 33(50):1937-8. PubMed ID: 733620 [No Abstract] [Full Text] [Related]
10. Clinical and microbiologic consequences of amikacin use during a 42-month period. Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526 [TBL] [Abstract][Full Text] [Related]
11. Antimicrobial agents--Part II. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin. Brewer NS Mayo Clin Proc; 1977 Nov; 52(11):675-9. PubMed ID: 336988 [TBL] [Abstract][Full Text] [Related]
16. Gentamicin-resistant gram-negative bacilli in hospital patients. Part II. In vitro aspects including susceptibility to tobramycin and amikacin. Block CS; Fabian B; Robinson RG S Afr Med J; 1978 Mar; 53(11):396-99. PubMed ID: 675374 [TBL] [Abstract][Full Text] [Related]
18. Replacement of gentamicin by amikacin as a means of decreasing gentamicin resistance of gram-negative rods in a neonatal intensive care unit. Wielunsky E; Drucker M; Cohen T; Reisner SH Isr J Med Sci; 1983 Nov; 19(11):1006-8. PubMed ID: 6662682 [TBL] [Abstract][Full Text] [Related]
19. Amikacin. Gleckman R Am Fam Physician; 1976 Dec; 14(6):75. PubMed ID: 998471 [No Abstract] [Full Text] [Related]
20. Amikacin in treatment of infections caused by gram-negative bacteria resistant to gentamicin and other aminoglycosides: clinical and bacteriologic results. Daikos GK; Kosmidis JC; Hamilton-Miller JM; Brumfitt W J Infect Dis; 1976 Nov; 134 SUPPL():S286-90. PubMed ID: 993623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]